Protein tyrosine kinase inhibitors in cancer therapy

被引：5

作者：

Boutayeb, S. ^{[1
]}

Zakkouri, F. Z. ^{[1
]}

Aitelhaj, M. ^{[1
]}

Mesmoudi, M. ^{[1
]}

Boutayeb, A. ^{[2
]}

Boutayeb, W. ^{[2
]}

Mrabti, H. ^{[1
]}

Errihani, H. ^{[1
]}

机构：

[1] CHU Ibn Slum, Inst Natl Oncol, Serv Oncol Med, Rabat, Morocco

[2] Univ Mohammed 1, Fac Sci, Unite Biostat, Oujda, Morocco

来源：

PATHOLOGIE BIOLOGIE | 2012年 / 60卷 / 04期

关键词：

Tyrosine kinase inhibitor; Cancer; Signal transduction; CELL LUNG-CANCER; PHASE-III; IMATINIB MESYLATE; DOUBLE-BLIND; VANDETANIB; SUNITINIB; ERLOTINIB; 1ST-LINE;

D O I：

10.1016/j.patbio.2012.05.007

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

The tyrosine kinase inhibitors (TKI) are small molecules of low molecular weight that inhibit tyrosine kinases, enzymes responsible for the activation of signal transduction cascades. Currently, a number of TKI received approval in various cancers, while others are in clinical development process: TKI are specifically clinically active when they target a tyrosine kinase (TK) with constitutional activity subsequent to a mutation, being then a master-gene driving transformation and tumour progression. Already, this drug-family provides a major therapeutic weapon against cancer. (C) 2012 Elsevier Masson SAS. All rights reserved.

引用

页码：229 / 233

页数：5

共 28 条

[1]

Baselga J, SAN ANT BREAST CANC

[2]

Bouyer F, 2010, ACTUAL PHARM, V498, P41

[3] A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses [J].

Cameron, David ;

Casey, Michelle ;

Press, Michael ;

Lindquist, Deborah ;

Pienkowski, Tadeusz ;

Romieu, C. Gilles ;

Chan, Stephen ;

Jagiello-Gruszfeld, Agnieszka ;

Kaufman, Bella ;

Crown, John ;

Chan, Arlene ;

Campone, Mario ;

Viens, Patrice ;

Davidson, Neville ;

Gorbounova, Vera ;

Raats, Johannes Isaac ;

Skarlos, Dimosthenis ;

Newstat, Beth ;

Roychowdhury, Debasish ;

Paoletti, Paolo ;

Oliva, Cristina ;

Rubin, Stephen ;

Stein, Steven ;

Geyer, Charles E. .

BREAST CANCER RESEARCH AND TREATMENT, 2008, 112 (03) :533-543

[4] ONCOGENES AND SIGNAL TRANSDUCTION [J].

CANTLEY, LC ;

AUGER, KR ;

CARPENTER, C ;

DUCKWORTH, B ;

GRAZIANI, A ;

KAPELLER, R ;

SOLTOFF, S .

CELL, 1991, 64 (02) :281-302

[5] Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues [J].

Christoffersen, Thoralf ;

Guren, Tormod K. ;

Spindler, Karen-Lise Garm ;

Dahl, Olav ;

Lonning, Per Eystein ;

Gjertsen, Bjorn Tore .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 625 (1-3) :6-22

[6] Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial [J].

DeMatteo, Ronald P. ;

Ballman, Karla V. ;

Antonescu, Cristina R. ;

Maki, Robert G. ;

Pisters, Peter W. T. ;

Demetri, George D. ;

Blackstein, Martin E. ;

Blanke, Charles D. ;

von Mehren, Margaret ;

Brennan, Murray F. ;

Patel, Shreyaskumar ;

McCarter, Martin D. ;

Polikoff, Jonathan A. ;

Tan, Benjamin R. ;

Owzar, Kouros .

LANCET, 2009, 373 (9669) :1097-1104

[7] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].

Demetri, GD ;

von Mehren, M ;

Blanke, CD ;

Van den Abbeele, AD ;

Eisenberg, B ;

Roberts, PJ ;

Heinrich, MC ;

Tuveson, DA ;

Singer, S ;

Janicek, M ;

Fletcher, JA ;

Silverman, SG ;

Silberman, SL ;

Capdeville, R ;

Kiese, B ;

Peng, B ;

Dimitrijevic, S ;

Druker, BJ ;

Corless, C ;

Fletcher, CDM ;

Joensuu, H .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480

[8] Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial [J].

Demetri, George D. ;

van Oosterom, Allan T. ;

Garrett, Christopher R. ;

Blackstein, Martin E. ;

Shah, Manisha H. ;

Verweij, Jaap ;

McArthur, Grant ;

Judson, Ian R. ;

Heinrich, Michael C. ;

Morgan, Jeffrey A. ;

Desai, Jayesh ;

D Fletcher, Christopher ;

George, Suzanne ;

Bello, Carlo L. ;

Huang, Xin ;

Baum, Charles M. ;

Casali, Paolo G. .

LANCET, 2006, 368 (9544) :1329-1338

[9] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[10]

Faure S, 2010, ACTUAL PHARM, V498, P49

← 1 2 3 →